Meeting
2018 ASCO Annual Meeting
Examining progression free survival (PFS), overall survival (OS), and toxicities of palbociclib in a geriatric population.
Authors
Katherine Clifton
The University of Texas MD Anderson Cancer Center, Houston, TX
Katherine Clifton , Jaime Kimmel , Jennifer Keating Litton , Debu Tripathy , Meghan Sri Karuturi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Geriatric Oncology
Citation
J Clin Oncol 36, 2018 (suppl; abstr 10039)
DOI
10.1200/JCO.2018.36.15_suppl.10039
Abstract #
10039
Poster Bd #
27
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Regorafenib in older adults with metastatic colorectal cancer: A multi-center, single arm phase II trial.
First Author: Nabeel Badri
Poster
2023 ASCO Annual Meeting
A phase I trial of palbociclib (palbo) and bosutinib (bos) with fulvestrant (fulv) in patients (pts) with hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) refractory to an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).
First Author: Candace Bavette Mainor
Poster
2023 ASCO Annual Meeting
BLU-222, an oral, potent, and selective CDK2 inhibitor, in patients with advanced solid tumors: Phase 1 monotherapy dose escalation.
First Author: Manish R. Patel
Poster
2022 ASCO Annual Meeting
A novel analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and provides an option for efficacy assessments that could accelerate drug approvals.
First Author: Celine Yeh